Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Earnings Calls In Brief

This article was originally published in The Gray Sheet

Executive Summary

J&J/Synthes deal on track

You may also be interested in...



And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market

The first company to enter the drug-eluting stent market will now be the first to depart.

New Products In Brief

J&J/Codman’s Orbit Galaxy

Abbott Expects To Resume Shipments Of Recalled MitraClip In Several Months

Abbott expects it will take several months to resume shipments of its MitraClip transcatheter mitral valve repair system following a voluntary global recall, but the firm says the recall is not likely to impact anticipated U.S. approval of the device later this year.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT030365

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel